<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Hair Loss, Explained on Medium]]></title>
        <description><![CDATA[Stories by Hair Loss, Explained on Medium]]></description>
        <link>https://medium.com/@hairlossexplained?source=rss-4f2829a80b2a------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*4GF1vJYeJVFV6L0Psw0ySg.png</url>
            <title>Stories by Hair Loss, Explained on Medium</title>
            <link>https://medium.com/@hairlossexplained?source=rss-4f2829a80b2a------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Thu, 19 Nov 2026 16:37:58 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@hairlossexplained/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Hair Transplant Before and After: What I Check Before I Trust a Result]]></title>
            <description><![CDATA[<div class="medium-feed-item"><p class="medium-feed-image"><a href="https://medium.com/illumination/hair-transplant-before-and-after-what-i-check-before-i-trust-a-result-b859f96dc18f?source=rss-4f2829a80b2a------2"><img src="https://cdn-images-1.medium.com/max/1400/1*RzXDG6Hz5I9YxCpS6fZFow.jpeg" width="1400"></a></p><p class="medium-feed-snippet">What I look at when patients show me a clinic gallery, including the one photo most galleries leave out</p><p class="medium-feed-link"><a href="https://medium.com/illumination/hair-transplant-before-and-after-what-i-check-before-i-trust-a-result-b859f96dc18f?source=rss-4f2829a80b2a------2">Continue reading on ILLUMINATION »</a></p></div>]]></description>
            <link>https://medium.com/illumination/hair-transplant-before-and-after-what-i-check-before-i-trust-a-result-b859f96dc18f?source=rss-4f2829a80b2a------2</link>
            <guid isPermaLink="false">https://medium.com/p/b859f96dc18f</guid>
            <category><![CDATA[wellness]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[hair-transplant]]></category>
            <category><![CDATA[hair-loss]]></category>
            <category><![CDATA[mens-health]]></category>
            <dc:creator><![CDATA[Hair Loss, Explained]]></dc:creator>
            <pubDate>Tue, 17 Nov 2026 14:37:11 GMT</pubDate>
            <atom:updated>2026-11-17T14:37:11.060Z</atom:updated>
        </item>
        <item>
            <title><![CDATA[PRP vs Exosomes for Hair Loss: What the Clinical Evidence Says]]></title>
            <description><![CDATA[<div class="medium-feed-item"><p class="medium-feed-image"><a href="https://medium.com/illumination/prp-vs-exosomes-for-hair-loss-what-the-clinical-evidence-says-300310c75d98?source=rss-4f2829a80b2a------2"><img src="https://cdn-images-1.medium.com/max/2000/1*uRaYb1WKZH9XIG1GOcdlWQ.jpeg" width="2000"></a></p><p class="medium-feed-snippet">PRP has years of human research behind it. Exosomes are less standardised and still experimental. Here&#x2019;s where the evidence stands.</p><p class="medium-feed-link"><a href="https://medium.com/illumination/prp-vs-exosomes-for-hair-loss-what-the-clinical-evidence-says-300310c75d98?source=rss-4f2829a80b2a------2">Continue reading on ILLUMINATION »</a></p></div>]]></description>
            <link>https://medium.com/illumination/prp-vs-exosomes-for-hair-loss-what-the-clinical-evidence-says-300310c75d98?source=rss-4f2829a80b2a------2</link>
            <guid isPermaLink="false">https://medium.com/p/300310c75d98</guid>
            <category><![CDATA[exosome]]></category>
            <category><![CDATA[regenerative-medicine]]></category>
            <category><![CDATA[prp-therapy]]></category>
            <category><![CDATA[hair-loss]]></category>
            <category><![CDATA[hair-transplant]]></category>
            <dc:creator><![CDATA[Hair Loss, Explained]]></dc:creator>
            <pubDate>Thu, 12 Nov 2026 20:58:55 GMT</pubDate>
            <atom:updated>2026-11-12T20:58:55.555Z</atom:updated>
        </item>
        <item>
            <title><![CDATA[The Most Important Number in the New Hair Loss Pill Trial Is 6.6]]></title>
            <description><![CDATA[<div class="medium-feed-item"><p class="medium-feed-image"><a href="https://medium.com/illumination/the-most-important-number-in-the-new-hair-loss-pill-trial-is-6-6-fa96f7b434c7?source=rss-4f2829a80b2a------2"><img src="https://cdn-images-1.medium.com/max/1672/1*K_gWhYT8SnW3Cs4zuD_TqA.png" width="1672"></a></p><p class="medium-feed-snippet">The headline figure was a gain of 36.4 hairs. The placebo group gained 6.6, and a third of those men said they could see an improvement.</p><p class="medium-feed-link"><a href="https://medium.com/illumination/the-most-important-number-in-the-new-hair-loss-pill-trial-is-6-6-fa96f7b434c7?source=rss-4f2829a80b2a------2">Continue reading on ILLUMINATION »</a></p></div>]]></description>
            <link>https://medium.com/illumination/the-most-important-number-in-the-new-hair-loss-pill-trial-is-6-6-fa96f7b434c7?source=rss-4f2829a80b2a------2</link>
            <guid isPermaLink="false">https://medium.com/p/fa96f7b434c7</guid>
            <category><![CDATA[mens-health]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[clinical-trials]]></category>
            <category><![CDATA[hair-loss]]></category>
            <category><![CDATA[science]]></category>
            <dc:creator><![CDATA[Hair Loss, Explained]]></dc:creator>
            <pubDate>Thu, 22 Oct 2026 14:29:52 GMT</pubDate>
            <atom:updated>2026-10-22T14:29:52.213Z</atom:updated>
        </item>
        <item>
            <title><![CDATA[Women With Hair Loss Have One Approved Medication. The Rest Was Never Properly Tested.]]></title>
            <description><![CDATA[<div class="medium-feed-item"><p class="medium-feed-image"><a href="https://medium.com/illumination/women-with-hair-loss-have-one-approved-medication-the-rest-was-never-properly-tested-648d54edd8e3?source=rss-4f2829a80b2a------2"><img src="https://cdn-images-1.medium.com/max/1536/1*ZaA1VKgPdszzcRrZkm0fIA.png" width="1536"></a></p><p class="medium-feed-snippet">Twenty years of prescribing, and nobody had to answer for it while patients paid the bill themselves.</p><p class="medium-feed-link"><a href="https://medium.com/illumination/women-with-hair-loss-have-one-approved-medication-the-rest-was-never-properly-tested-648d54edd8e3?source=rss-4f2829a80b2a------2">Continue reading on ILLUMINATION »</a></p></div>]]></description>
            <link>https://medium.com/illumination/women-with-hair-loss-have-one-approved-medication-the-rest-was-never-properly-tested-648d54edd8e3?source=rss-4f2829a80b2a------2</link>
            <guid isPermaLink="false">https://medium.com/p/648d54edd8e3</guid>
            <category><![CDATA[dermatology]]></category>
            <category><![CDATA[womens-health]]></category>
            <category><![CDATA[health-insurance]]></category>
            <category><![CDATA[hair-loss]]></category>
            <category><![CDATA[clinical-trials]]></category>
            <dc:creator><![CDATA[Hair Loss, Explained]]></dc:creator>
            <pubDate>Mon, 12 Oct 2026 12:14:32 GMT</pubDate>
            <atom:updated>2026-10-12T12:14:32.673Z</atom:updated>
        </item>
        <item>
            <title><![CDATA[South Korea Asked How Bald Is Bald Enough. Nobody Could Answer It.]]></title>
            <description><![CDATA[<div class="medium-feed-item"><p class="medium-feed-image"><a href="https://medium.com/illumination/south-korea-asked-how-bald-is-bald-enough-nobody-could-answer-it-138595e56e89?source=rss-4f2829a80b2a------2"><img src="https://cdn-images-1.medium.com/max/1672/1*Gw9j1QSOJM8MmwPjUkcK7A.png" width="1672"></a></p><p class="medium-feed-snippet">One government, one week, two opposite answers about whether hair loss counts as a medical problem.</p><p class="medium-feed-link"><a href="https://medium.com/illumination/south-korea-asked-how-bald-is-bald-enough-nobody-could-answer-it-138595e56e89?source=rss-4f2829a80b2a------2">Continue reading on ILLUMINATION »</a></p></div>]]></description>
            <link>https://medium.com/illumination/south-korea-asked-how-bald-is-bald-enough-nobody-could-answer-it-138595e56e89?source=rss-4f2829a80b2a------2</link>
            <guid isPermaLink="false">https://medium.com/p/138595e56e89</guid>
            <category><![CDATA[south-korea]]></category>
            <category><![CDATA[dermatology]]></category>
            <category><![CDATA[hair-loss]]></category>
            <category><![CDATA[healthcare-policy]]></category>
            <category><![CDATA[health-insurance]]></category>
            <dc:creator><![CDATA[Hair Loss, Explained]]></dc:creator>
            <pubDate>Mon, 05 Oct 2026 09:02:00 GMT</pubDate>
            <atom:updated>2026-10-05T09:02:00.161Z</atom:updated>
        </item>
        <item>
            <title><![CDATA[Traction Alopecia Is The One Hair Loss You Can Stop Without Medication.]]></title>
            <description><![CDATA[<div class="medium-feed-item"><p class="medium-feed-image"><a href="https://medium.com/illumination/traction-alopecia-is-the-one-hair-loss-you-can-stop-without-medication-eee1e054b1e8?source=rss-4f2829a80b2a------2"><img src="https://cdn-images-1.medium.com/max/1400/1*tivPNov746YZuu6kpue2YA.jpeg" width="1400"></a></p><p class="medium-feed-snippet">It is caused by tension rather than hormones, which makes it the one pattern your own choices can halt. The window for that closes quietly.</p><p class="medium-feed-link"><a href="https://medium.com/illumination/traction-alopecia-is-the-one-hair-loss-you-can-stop-without-medication-eee1e054b1e8?source=rss-4f2829a80b2a------2">Continue reading on ILLUMINATION »</a></p></div>]]></description>
            <link>https://medium.com/illumination/traction-alopecia-is-the-one-hair-loss-you-can-stop-without-medication-eee1e054b1e8?source=rss-4f2829a80b2a------2</link>
            <guid isPermaLink="false">https://medium.com/p/eee1e054b1e8</guid>
            <category><![CDATA[traction-alopecia]]></category>
            <category><![CDATA[hair-loss]]></category>
            <category><![CDATA[natural-hair]]></category>
            <category><![CDATA[afro-hair]]></category>
            <category><![CDATA[womens-health]]></category>
            <dc:creator><![CDATA[Hair Loss, Explained]]></dc:creator>
            <pubDate>Fri, 25 Sep 2026 17:28:03 GMT</pubDate>
            <atom:updated>2026-09-25T17:28:03.600Z</atom:updated>
        </item>
        <item>
            <title><![CDATA[I Went Looking for the Evidence Behind What We Tell Patients With Diabetes. There Is None.]]></title>
            <link>https://medium.com/illumination/i-went-looking-for-the-evidence-behind-what-we-tell-patients-with-diabetes-there-is-none-a9f10aae9704?source=rss-4f2829a80b2a------2</link>
            <guid isPermaLink="false">https://medium.com/p/a9f10aae9704</guid>
            <category><![CDATA[hair-transplant]]></category>
            <category><![CDATA[hair-loss]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[evidence-based-medicine]]></category>
            <category><![CDATA[diabetes]]></category>
            <dc:creator><![CDATA[Hair Loss, Explained]]></dc:creator>
            <pubDate>Fri, 18 Sep 2026 05:16:50 GMT</pubDate>
            <atom:updated>2026-09-18T05:16:50.616Z</atom:updated>
            <content:encoded><![CDATA[<h4>Every clinic says a hair transplant is fine as long as your blood sugar is controlled. I could not find a single study that has tested whether that is true. Including ours.</h4><figure><img alt="A blood glucose meter on a wooden table showing a reading of 104 mg/dL, beside a lancet device and a vial of test strips." src="https://cdn-images-1.medium.com/max/1024/1*l8oNoGsTW2S4CUJvfAiH4g.jpeg" /><figcaption><em>Image generated with AI.</em></figcaption></figure><p>Most people assume the risk in operating on someone with diabetes is infection. That is where the thinking usually stops, and the real problem sits further back than that. Nobody has checked.</p><p>A patient with diabetes who searches for whether they can have a hair transplant will find the same sentence everywhere, on our website as well as on everyone else’s. Yes, provided your diabetes is well controlled. I have said it in consultations for years. Two months ago I went looking for what it rests on, because our clinic had spent six months recording what happened in 53 of our own diabetic patients and I wanted to know what the existing evidence would let me compare that against.</p><p>There is no existing evidence. Not thin evidence. None.</p><h3>What I Searched For, and What Came Back</h3><p>I was looking for something simple: graft survival, complication rates, infection rates or healing outcomes in patients with diabetes, set against patients without.</p><p>The most recent systematic review of hair transplant complications was published this year. It pooled 45 articles covering 2,353 patients and 27 individual case reports. It contains no analysis of comorbidity at all. Diabetes is not in it, and neither is smoking or vascular disease. The largest single complication series in the field, 425 consecutive patients across 533 procedures with a year of follow-up, reports an overall complication rate of 4.7% and does not mention diabetes anywhere in the paper. The standard guidelines of care for hair transplantation do not list diabetes as a contraindication, a relative contraindication, or a precaution. They do not list it at all.</p><p>The claim does appear in review articles. Diabetes turns up in lists of systemic conditions that “can compromise scalp microcirculation and delay wound healing.” Every one of those statements I followed traced back to general principles of wound healing after an operation, or to nothing. None traced to a study of hair restoration in diabetic patients, because there is not one.</p><p>So when a clinic tells a patient with diabetes that the operation is fine if their glucose is controlled, that sentence is not a summary of evidence. It is a reasonable guess that the whole field has been repeating for long enough that it sounds like a finding.</p><h3>What is Established</h3><p>Something real does sit underneath the guess, and it is worth being precise about what it is.</p><p>Diabetes reduces the responsiveness of the small vessels in the skin. That much is well demonstrated. A meta-analysis pooling 13 studies and 857 people compared the skin microvascular response to local heating in diabetic patients against healthy controls and found it reduced, with a pooled standardized mean difference of −0.78. That is a substantial effect and it is not in doubt.</p><p>A transplanted follicle depends on exactly that circulation. It arrives with no blood supply of its own, lives for the first few days on what soaks in from the tissue around it, and then on new vessels growing in.</p><p>Put those two facts together and you get the reasoning the whole field runs on. It is sound reasoning. It has simply never been tested at the point where it matters, which is whether transplanted hair grows less well in people with diabetes, and if so, in whom.</p><h3>What is Not Established, Including the Thing I Expected to Find</h3><p>I went in with a hypothesis. Our own recording had been organised by how long each patient had lived with diabetes, and I expected the literature to support the idea that duration matters, that someone diagnosed twenty years ago is a different case from someone diagnosed last year even at the same HbA1c.</p><p>The evidence does not support that, and I would rather say so than quietly leave it out.</p><p>The same meta-analysis that established the reduced microvascular response tested duration directly as a moderating variable, alongside age, BMI and HbA1c. It found no significant effect for any of them, and concluded that diabetes itself causes the microvascular dysfunction rather than the years accumulating. A separate study of 119 patients with type 2 diabetes and peripheral arterial disease, average duration close to twenty years, measured skin oxygenation directly and built a regression model to find what predicted it. Duration did not survive into the model. Smoking, HbA1c and LDL cholesterol did, with smoking the strongest of them.</p><p>There is work pointing the other way, in children and adolescents with type 1 diabetes, and one 2024 paper carries the phrase “the impact of disease duration” in its title. Read the results and the comparison between its short-duration and long-duration groups was not significant on any measured parameter. I mention it because I nearly cited it on the strength of its title, which is a mistake I have made in print before and would rather not repeat.</p><p>So the honest position is that diabetes is robustly associated with poorer skin microcirculation, and that duration has not been shown to add anything on top of that. Current control and smoking sit on firmer ground than the years since diagnosis.</p><figure><img alt="One person pressing a fingertip of another person’s hand between thumb and forefinger, on a plain white surface." src="https://cdn-images-1.medium.com/max/1024/1*ente4n29hWWs0KHMSiFAxQ.jpeg" /><figcaption>The capillary refill test. Press, release, and count until the colour returns. Two clinicians timing the same patient often disagree by more than a second. Photo: Elithair</figcaption></figure><h3>Why I Am Not Showing You Our Own Numbers Yet</h3><p>We recorded blood supply at the recipient area in 53 patients with diabetes across the first half of 2024, and the figures did vary with how long people had been diabetic.</p><p>I am not going to put them in front of you, and the reason is the point of this article rather than an evasion of it.</p><p>When I went to check what our measurement could support, I found that the test itself has no validated basis for this use. The capillary refill test is what we and much of medicine use as a quick bedside read on whether blood is reaching tissue. The familiar threshold, two seconds, was examined in 1988 by researchers who wrote that there is no published evidence supporting that value. Measured in healthy volunteers, the upper limit of normal came out at around two seconds in adult men, 2.9 seconds in women and 4.5 seconds in the elderly. Cold hands moved the median from 1.3 seconds to 2.9. When two clinicians measure the same stable patient, the limits of agreement run from roughly 1.7 seconds below to 1.9 seconds above, and agreement on whether a patient is simply normal or abnormal reaches a kappa of 0.38.</p><p>A meta-analysis last year covering 23 studies and more than 60,000 patients found that the thresholds used across the literature ranged from two seconds to 4.9, with no consensus, and that the test predicted outcomes poorly even in the setting it was designed for.</p><p>That setting is acute circulatory failure. I could not find a single study validating capillary refill as a measure of chronic peripheral perfusion, against laser Doppler or oxygen pressure or capillaroscopy or anything else.</p><p>Which means our 53 patients were sorted by a test that is crude, observer-dependent, temperature-dependent, has no defensible threshold, and has never been shown to measure the thing we were using it to measure. The numbers may well be pointing at something real. I cannot tell you that they are, and publishing them as though I could would repeat the field’s original mistake in a new costume.</p><figure><img alt="A doctor in a white coat and gloves using a micropipette at a laboratory bench, with a rack of blood collection tubes in front of him." src="https://cdn-images-1.medium.com/max/1024/1*RMnxmj66oLl8hYt_Asz1HQ.jpeg" /><figcaption>Blood work in the clinic’s laboratory. Photo: Elithair</figcaption></figure><h3>What Would Settle It</h3><p>It is not complicated, which is the frustrating part.</p><p>A cohort of patients with diabetes and a matched group without. Perfusion at the recipient area measured with an instrument rather than a thumb. Ages recorded, HbA1c recorded, smoking recorded, duration recorded. Graft survival counted at twelve months inside a marked box of scalp, which is how survival is counted in the few places where it is counted at all.</p><p>That is one year and a few hundred patients. Our field performs hundreds of thousands of these operations a year and has not done it.</p><h3>What I Tell Patients Now</h3><p>That the operation is very probably fine, that this is a judgement rather than a finding, and that I would rather they heard the difference from me.</p><p>That the things with real evidence behind them are the ordinary ones. Glycaemic control keeps surviving in the studies that test it. Smoking outperformed diabetes duration as a predictor of skin oxygenation in the one study I found that put the two head to head, which I did not expect. And how their own body has healed in the past has already told them something the literature has not.</p><p>And that if a clinic gives them a confident answer about their scalp and their diabetes, they are entitled to ask what it is based on. I have looked. The answer is that it is based on all of us agreeing with each other.</p><h4>Selected References</h4><ul><li>Fuchs D, Dupon PP, Schaap LA, Draijer R.<a href="https://ncbi.nlm.nih.gov/pmc/articles/PMC5244618"> The association between diabetes and dermal microvascular dysfunction non-invasively assessed by laser Doppler with local thermal hyperemia: a systematic review with meta-analysis</a>. <em>Cardiovascular Diabetology</em> 2017;16:11.</li><li>Bulum T, Brkljačić N, Tičinović Ivančić A, et al.<a href="https://www.mdpi.com/2227-9059/12/2/381"> Transcutaneous oxygen pressure in type 2 diabetes with peripheral arterial disease</a>. <em>Biomedicines</em> 2024;12(2):381.</li><li>Neubauer-Geryk J, Wielicka M, Hoffmann M, et al.<a href="https://www.mdpi.com/2227-9059/12/5/1020"> The impact of disease duration on microcirculatory dysfunction in young patients with uncomplicated type 1 diabetes</a>. <em>Biomedicines</em> 2024;12(5):1020.</li><li>Wielicka M, Neubauer-Geryk J, Brandt-Varma A, et al.<a href="https://www.termedia.pl/Skin-microvascular-circulation-is-not-affected-by-diabetes-duration-in-young-patients-with-non-complicated-type-1-diabetes-mellitus,138,38558,1,1.html"> Skin microvascular circulation is not affected by diabetes duration in young patients with non-complicated type 1 diabetes mellitus</a>. <em>Pediatric Endocrinology Diabetes and Metabolism</em> 2019;25(4):183–187.</li><li>Anderson B, Kelly AM, Kerr D, Jolley D.<a href="https://journals.sagepub.com/doi/10.1177/102490790801500202"> Impact of patient and environmental factors on capillary refill time in adults</a>. <em>Hong Kong Journal of Emergency Medicine</em> 2008.</li><li>Jacquet-Lagrèze M, et al.<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10693708/"> Capillary refill time for the prognosis of acute circulatory failure: systematic review and meta-analysis</a>. <em>Critical Care</em> 2023.</li><li>Patwardhan N, Mysore V.<a href="https://ijdvl.com/hair-transplantation-standard-guidelines-of-care/"> Hair transplantation: standard guidelines of care</a>. <em>Indian Journal of Dermatology, Venereology and Leprology</em> 2008.</li><li>Schriger DL, Baraff L.<a href="https://www.sciencedirect.com/science/article/abs/pii/S0196064488806759"> Defining normal capillary refill: variation with age, sex, and temperature</a>. <em>Annals of Emergency Medicine</em> 1988;17(9):932–935.</li><li>Khatib M, Skorochod R, Wolf Y.<a href="https://link.springer.com/article/10.1007/s00266-025-05125-y"> Complications of hair transplantation: a systematic review and meta-analysis</a>. <em>Aesthetic Plastic Surgery</em> 2025.</li><li>Salanitri S, Gonçalves AJ, Helene A, Lopes FHJ.<a href="https://academic.oup.com/asj/article-abstract/29/1/72/295467"> Surgical complications in hair transplantation: a series of 533 procedures</a>. <em>Aesthetic Surgery Journal</em> 2009;29(1):72.</li></ul><h4>About the Author</h4><p><strong>Dr. Aziz Balwi<br></strong>Medical Director<br><em>Hair Loss, Explained</em></p><p>Dr. Aziz Balwi specializes in hair restoration with a clinical focus on donor management, long-term transplant planning, and patient-specific treatment strategies.</p><p><strong>Hair Loss, Explained<br></strong>This article is part of the <em>Hair Loss, Explained</em> series, which explores the biology of hair loss, treatment limitations, and emerging research in hair restoration.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=a9f10aae9704" width="1" height="1" alt=""><hr><p><a href="https://medium.com/illumination/i-went-looking-for-the-evidence-behind-what-we-tell-patients-with-diabetes-there-is-none-a9f10aae9704">I Went Looking for the Evidence Behind What We Tell Patients With Diabetes. There Is None.</a> was originally published in <a href="https://medium.com/illumination">ILLUMINATION</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[I Co-Wrote a Review of Exosomes for Hair Loss. Here Is What We Could Not Find.]]></title>
            <link>https://medium.com/illumination/i-co-wrote-a-review-of-exosomes-for-hair-loss-here-is-what-we-could-not-find-5e2bfafbac66?source=rss-4f2829a80b2a------2</link>
            <guid isPermaLink="false">https://medium.com/p/5e2bfafbac66</guid>
            <category><![CDATA[hair-transplant]]></category>
            <category><![CDATA[evidence-based-medicine]]></category>
            <category><![CDATA[hair-loss]]></category>
            <category><![CDATA[exosome]]></category>
            <category><![CDATA[regenerative-medicine]]></category>
            <dc:creator><![CDATA[Hair Loss, Explained]]></dc:creator>
            <pubDate>Fri, 11 Sep 2026 15:41:09 GMT</pubDate>
            <atom:updated>2026-09-11T15:41:09.506Z</atom:updated>
            <content:encoded><![CDATA[<h4>Nobody can tell you what was in the syringe. That turns out to be a bigger problem than whether it works.</h4><figure><img alt="Dr. Balwi at a desk, annotating a printed document, with hair transplantation textbooks beside him." src="https://cdn-images-1.medium.com/max/1024/1*5wijk58AqKphfZbE3vUcZA.jpeg" /><figcaption>image by author</figcaption></figure><p>People arrive already sold. Exosomes, regenerative, the next thing after PRP, sometimes at a price that is a real fraction of what an operation costs. By the time it reaches me it is usually not a question.</p><p>A colleague and I published a review earlier this year of the treatments used alongside hair transplantation. Platelet-rich plasma, low-level laser, microneedling, exosomes. I want to write about the last of those, because doing the reading changed what I thought, and not in the direction I expected.</p><h3>The Easy Part First</h3><p>The clinical evidence for exosomes in hair transplantation is thin. Most of what exists is experimental models or small early-stage trials, and the methods differ so much between them that you cannot pool the results. There are no high-quality randomised controlled trials of exosomes as an adjunct to a transplant. Not a thin literature. Not one.</p><p>I want to be careful, because “no evidence” gets heard as “does not work” and those are different sentences. The question has not been asked properly yet. That is all this says.</p><h3>The Word Does Not Name One Thing</h3><p>What surprised me was somewhere else, and I had not thought about it before I did the reading.</p><p>Exosomes is not one product. Two quite different things are sold under the word. There are platelet-derived vesicles, which come off platelets when they are activated, and which are broadly part of what PRP is doing already. And there are cell-derived exosomes, usually discussed in the context of mesenchymal stromal cells. Those differ in what they contain, how they are made, what characterisation they need, and how regulators treat them. A clinic that says it offers exosomes has told you close to nothing.</p><figure><img alt="A diagram showing the word Exosomes splitting into two products, platelet-derived vesicles and cell-derived exosomes, with four ways they differ listed underneath: composition, production, characterisation required, and regulatory status." src="https://cdn-images-1.medium.com/max/1024/1*VBre-YNRVV7cvGT0nkgsbw.png" /><figcaption>Based on Balwi and Koldas, Frontiers in Medicine, 2026.</figcaption></figure><p>Underneath that sits a more basic problem. There is a published minimum standard for reporting extracellular vesicle studies. The field’s own reviews still find wide variation in sources, in product characterisation, in delivery, in protocols, and in how outcomes get reported. Which is why comparing two studies, or defining a dose-response relationship in a way that means something clinically, remains difficult.</p><p>Follow that one more step. If the product is not characterised, there is no dose. And if there is no dose, nobody in the room can tell you how much of the active material went into your scalp. Not the patient. Not the person holding the syringe. That is less a gap in the evidence than the missing unit you would need before evidence was possible at all.</p><h3>Regulation is Not a Technicality Here</h3><p>PRP has a property that gets lost in the comparison. It is your own blood, spun and put back. That is a simple object.</p><p>Exosome products are not simple objects. How they are classified depends on where they came from, how much they have been manipulated, what they are for, and which country you are standing in. They bring expectations that autologous PRP does not: manufacturing controls, characterisation, efficacy testing, sterility assurance, batch consistency. The safety question sits in the same place. My concern is not the biology so much as contamination and batch-to-batch variability in something made elsewhere and shipped in.</p><p>Which is why the questions worth asking are boring ones. Which of the two categories is this? Who manufactured it? What characterisation came with the batch. Under what regulatory route is it being supplied here.</p><p>A vague answer to those is itself an answer.</p><h3>Investigational</h3><p>That is the word our review settles on. Exosome-based interventions should currently be considered investigational.</p><p>It is a dull word and I would rather have been able to write a better one. But it does not mean useless. It means this may well turn out to work, and that for now the person paying is carrying the risk instead of the evidence.</p><p>Which puts the obligation on the clinic rather than the patient. If something is investigational, whoever offers it owes you an account of the evidence, of the missing protocols, and of where the regulation sits, before you decide. Not buried in a consent form. Out loud, in the room.</p><p>I am comfortable holding that while the field catches up. We do not offer exosomes today, and I would not turn that into a principle. The position is conditional rather than permanent. When the characterisation and the dosing arrive, the argument in this piece stops applying, and I would expect to change my mind in public.</p><p>What would not change is the disclosure. If we ever put this in front of a patient, it goes in front of them as investigational, with the evidence base, the absent protocols and the regulatory position said first and said plainly. That is the standard I would want applied to me, and I would rather publish it now, while it costs us nothing, than after we have something to sell.</p><h3>Where Our Review is Weak</h3><p>Ours is a narrative review, not a meta-analysis, and we did not implement full PRISMA. It carries the selection bias narrative reviews carry. We said so in the paper.</p><p>It also has a date on it, and that matters more than people usually allow. Our search closed in February 2025. The paper came out in July 2026. So roughly eighteen months sit outside what we looked at, including newer work on the regulatory and safety side. If the picture has moved, our review would not know.</p><p>I mention it because it is the standard I would want applied to anybody quoting a paper at me. A review with a search window is a photograph, not a live feed.</p><h3>What I Say When Someone Asks</h3><p>That the biology is interesting and I hope it goes somewhere. That the evidence is not there. And that the thing missing is not a trial but a unit of measurement, which is the harder of the two, because you can run a trial in a couple of years and you cannot run one at all until you can say what you gave.</p><p>If they want a number today, PRP has randomised trials behind it showing density increases of roughly ten to thirty hairs per square centimetre. That is a modest result, measured properly. I would take it over a large claim with nothing underneath.</p><figure><img alt="A comparison showing PRP at ten to thirty additional hairs per square centimetre from randomised trials, and exosomes with no figure, because without standardised characterisation there is no unit to express a result in." src="https://cdn-images-1.medium.com/max/1024/1*MBGdY7HVM1DUWazHub_iPQ.png" /><figcaption>Based on Balwi and Koldas, Frontiers in Medicine, 2026.</figcaption></figure><p>And the thing worth most to them is still the one nobody has a reason to sell hard, which is keeping the hair they have got.</p><h4>Selected References</h4><ul><li><a href="https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2026.1820122/full">Balwi A, Koldas T. “Adjunctive regenerative therapies in hair transplantation: a comprehensive review of platelet-rich plasma, exosomes, and emerging methods.” <em>Frontiers in Medicine</em>, 2 July 2026.</a></li><li><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC13372975/">https://pmc.ncbi.nlm.nih.gov/articles/PMC13372975/</a></li><li><a href="https://isevjournals.onlinelibrary.wiley.com/doi/10.1002/jev2.12404">Welsh JA et al. “Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches.” <em>Journal of Extracellular Vesicles</em>, 2024.</a></li><li><a href="https://elithair.com/uk/blog/exosome-therapy-for-hair-loss/">Exosome Hair Loss Therapy: Safety &amp; UK Legal Status</a></li><li><a href="https://elithair.com/uk/treatment/prp-treatment/">PRP Hair Treatment UK</a></li><li><a href="https://medium.com/illumination/most-men-who-ask-me-for-an-operation-should-not-have-one-yet-b60a685e60f0">“Most Men Who Ask Me for an Operation Should Not Have One Yet”, Medium.</a></li></ul><h4>About the Author</h4><p><strong>Dr. Aziz Balwi<br></strong>Medical Director<br><em>Hair Loss, Explained</em></p><p>Dr. Aziz Balwi specializes in hair restoration with a clinical focus on donor management, long-term transplant planning, and patient-specific treatment strategies.</p><p><strong>Hair Loss, Explained<br></strong>This article is part of the <em>Hair Loss, Explained</em> series, which explores the biology of hair loss, treatment limitations, and emerging research in hair restoration.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=5e2bfafbac66" width="1" height="1" alt=""><hr><p><a href="https://medium.com/illumination/i-co-wrote-a-review-of-exosomes-for-hair-loss-here-is-what-we-could-not-find-5e2bfafbac66">I Co-Wrote a Review of Exosomes for Hair Loss. Here Is What We Could Not Find.</a> was originally published in <a href="https://medium.com/illumination">ILLUMINATION</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Nobody Posts Month Four]]></title>
            <link>https://medium.com/illumination/nobody-posts-month-four-de2eebe6ccbc?source=rss-4f2829a80b2a------2</link>
            <guid isPermaLink="false">https://medium.com/p/de2eebe6ccbc</guid>
            <category><![CDATA[hair-loss]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[hair-transplant]]></category>
            <category><![CDATA[mens-health]]></category>
            <category><![CDATA[body-image]]></category>
            <dc:creator><![CDATA[Hair Loss, Explained]]></dc:creator>
            <pubDate>Wed, 02 Sep 2026 17:53:03 GMT</pubDate>
            <atom:updated>2026-09-02T17:53:03.692Z</atom:updated>
            <content:encoded><![CDATA[<h4>The hardest part of a hair transplant is a measurement problem. For a minority of men it is not, and the research is quiet about them.</h4><figure><img alt="Close-up of a man’s scalp four months after a hair transplant. Fine hair lies across the mid-scalp with skin visible between the strands." src="https://cdn-images-1.medium.com/max/1024/1*-GElNlzoREV2pWnxz7cMAQ.png" /><figcaption>Month four. Credit: Elithair</figcaption></figure><p>There is a photograph almost nobody takes.</p><p>Search for hair transplant results and you get two kinds of pictures. The before, and the finished one. Day zero and month twelve. Try to find a good, honest, well lit photograph of a man at four months and you will be looking for a while.</p><p>That is not a conspiracy. It is just how people behave. You photograph the beginning because you have decided to do something about it, and you photograph the end because you are pleased. In the middle you take pictures constantly and show them to nobody, because as far as you can tell there is nothing to show. Multiply that by every man who has ever had the procedure and you end up with an internet where the middle of the process is missing.</p><p>Which leaves a man at four months with no honest comparison available to him. He has his own month four, and the only other thing he can find is somebody else’s month twelve. So he concludes he is behind.</p><p>I have watched patients do this for years. What I used to do about it was explain the biology. The transplanted hairs come out in the first weeks after they are placed, the follicle goes quiet for a while, then it starts producing again, and the surface lags a long way behind the work. All true. It almost never helps. The man sitting across from me has usually read all of that already, in more detail than I just gave it. He is not confused. He is looking at a photograph and the photograph is not moving.</p><p>So these days I talk about the photographs instead.</p><figure><img alt="A three by three grid of nine top-down photographs of the same man’s scalp, taken one month apart across nine consecutive months and presented out of order. The frames look almost identical to each other." src="https://cdn-images-1.medium.com/max/968/1*lUlTjqhzp79Wb4aqdvnaPQ.png" /><figcaption>9 consecutive months. Same patient, same angle, shuffled. One of them is month 4. The cover of this article is a detail from that frame, and it is the one at the top left. Credit: Elithair</figcaption></figure><h3>The instrument</h3><p>Hair grows about a centimetre a month. A transplanted follicle produces something meaningfully different over eight to twelve weeks, and in the crown it carries on changing until somewhere between fifteen and twenty-four months. That is the thing being measured.</p><p>Here is what it is being measured with. A phone, held at arm’s length, in a bathroom, at whatever hour of the day the anxiety happens to peak, under a light fixed to the ceiling and therefore pointing straight down at the exact part of the scalp he is worried about. Wet hair some days, dry others. Daily. Sometimes three times daily.</p><p>A man doing that has taken a hundred and twenty measurements by month four and learned nothing at all from any of them, while feeling as though he has been keeping a very close eye on things. What he has actually recorded is the weather in his bathroom.</p><figure><img alt="Two top-down photographs of the same scalp side by side, labelled month 9 and month 10. The month 9 frame is pale and cool under bathroom lighting. The month 10 frame is darker and warmer, taken in a different room." src="https://cdn-images-1.medium.com/max/1024/1*HbzJLV1R8E96KPWUzzyFJw.png" /><figcaption>30 days apart, same angle. Most of what changed between these two photographs is the room. Credit: Elithair</figcaption></figure><p>The fix for this is boring, which is probably why nobody follows it. Once a month. Same room, same hour, same distance, dry hair, the same few angles every time. Then do not look at the photograph you just took. Look at the whole set together. The set is the measurement.</p><p>I can be blunt about this because we do it. We photograph patients every month from five angles and we keep the sets complete, including the months where nothing appears to be happening. One of the men whose series went out this week has twelve consecutive monthly sets. His month one, on its own, is not an encouraging picture. Sitting in the sequence it is the most reassuring photograph in the whole set, because you can see what came next. Same photograph. Completely different meaning.</p><h3>The part I would rather not write</h3><p>Everything so far says the waiting is a perception problem, and for most men that is what it is. I do not want to leave it there, because it is not the whole picture and there is a study I keep coming back to.</p><p>In 2012 Rajendarsingh Rajput published a piece of work in <em>Hair Transplant Forum International</em>. He took a hundred hair loss patients and assessed them before their procedures, using modified versions of the Yale-Brown obsessive compulsive scale, the Sheehan disability scale, and a measure of appearance related distress. Twenty-seven percent came out at the severe level. High enough to raise the question of body dysmorphic disorder.</p><p>Then he assessed the same men eight months after their procedures. Most of them had improved considerably. The extreme band on the Yale-Brown measure emptied out entirely, which is the result you would want.</p><p>On the appearance distress measure, sixteen percent were still in the extreme band. Before their operations it had been eighteen.</p><p>Their hair had changed. The distress had moved by two points.</p><p>I am not going to pretend I know exactly what that means. It is one study, a hundred men, modified instruments, and appearance related distress is treatable whether or not anybody operates on anything. But it matches something I recognise from the consulting room, and I have never seen a clinic put it in writing. For a small number of men the hair is not the thing that hurts. We do the work, the work succeeds, and the feeling it was supposed to settle is still sitting there afterwards looking for some other detail to attach itself to.</p><p>If you are four months in and reading this, I am not diagnosing you and I would not try to from here. But there is a question worth asking yourself that nobody else is going to ask you, which is whether the version of you with good hair is definitely a calmer man than the one reading this. If that is not an easy yes, it is worth saying so out loud to somebody. It is a different problem. It has a different treatment. An operation is a poor tool for it and I would rather say that than sell you one.</p><h3>Which brings me to a problem with the study</h3><p>Rajput’s follow up was at eight months.</p><p>That is normal for this literature and it is a real weakness, because eight months is before the result has finished arriving. A hairline can be judged reasonably at nine to twelve months, and a crown keeps improving to fifteen, sometimes twenty-four.</p><figure><img alt="A timeline of the months following a hair transplant. One bar marks the hairline settling between months nine and twelve. A longer bar marks the crown still filling from month fifteen to month twenty-four. A marker at month eight shows where the satisfaction study took its measurements, which is before either bar begins." src="https://cdn-images-1.medium.com/max/1024/1*leZIl_HJ0n1nSIydhqaBAw.png" /><figcaption>A hairline can be judged fairly from 9months. A crown keeps filling to 15 or 27. The satisfaction data was collected at 8. Graphic: Elithair</figcaption></figure><p>So when a study reports that a proportion of patients are still dissatisfied, we cannot actually tell how much of that is lasting distress and how much is a photograph taken too early. Both readings fit the data. The study has no way to separate them, and neither do I.</p><p>I find that useful rather than irritating. It means the honest answer to “does the operation fix the distress” is that nobody knows the split, because the research keeps taking its measurements before the thing being measured has finished happening. Anyone who gives you a confident number in either direction is telling you something the evidence will not support.</p><h3>Things not to decide at month four</h3><p>Impatience is not a feeling that sits there quietly. It produces decisions, and a few of them do not come back.</p><p>The most common one is coming off the medication, on the reasoning that the operation is done and the job is finished. The grafts do not need it. The hair around them does. That argument deserves its own article and it is getting one, so I will leave it there.</p><p>Then there is starting something new in month two or three. Topical minoxidil shortens the resting phase, and one recognised consequence of that at the start of treatment is a period of increased shedding. Begin it in the middle of a post-operative shed and you now have two processes overlapping with no way of telling them apart. In my experience the patient blames the transplant, every time.</p><p>And the expensive one. Booking more work before the first has finished. Donor supply is finite, and patients underestimate how finite by a wide margin. Spending some of it at month five on an area that was going to fill in by itself by month twelve is the only mistake on this list you cannot undo.</p><h3>What I say now</h3><p>Photograph it monthly, not daily. Same room, same light, same angles. Judge the set, not the frame, and never the mirror.</p><p>Expect the crown last. Its lateness is not a verdict.</p><p>Change nothing at month four.</p><p>And if you arrive at twelve months with a good result and find that you are still checking, take that seriously rather than dismissing it, because it means the problem we solved and the problem you had were not the same problem. That is a conversation worth having. It is a better use of your evening than another photograph.</p><p>*** All photographs in this article are our patient’s own, taken monthly on his own phone across eleven months and published with his permission. Nothing has been retouched. The colour and lighting shift between frames because the rooms did.</p><h4>Selected References</h4><p><a href="https://www.ishrs-htforum.org/content/22/4/133">Rajput R. Evaluation of body dysmorphic disorder in hair loss patients and benefit after hair restoration. <em>Hair Transplant Forum International</em> 2012;22(4):133–135.</a><br><a href="https://www.ncbi.nlm.nih.gov/books/NBK513312/">Martel JL, Miao JH, Badri T, Hashmi MF. Anatomy, Hair. StatPearls, NCBI Bookshelf.</a><br><a href="https://www.ncbi.nlm.nih.gov/books/NBK482378/">Patel P, Nessel TA, Kumar DD. Minoxidil. StatPearls, NCBI Bookshelf.<br></a><a href="https://charlesmedicalgroup.com/plastic-surgery/hair-transplant-crown-restoration-challenges-explained/">Crown surface area, target density and maturity ranges: Charles Medical Group.</a></p><h4>About the Author</h4><p><strong>Dr. Aziz Balwi<br></strong>Medical Director<br><em>Hair Loss, Explained</em></p><p>Dr. Aziz Balwi specializes in hair restoration with a clinical focus on donor management, long-term transplant planning, and patient-specific treatment strategies.</p><p><strong>Hair Loss, Explained<br></strong>This article is part of the <em>Hair Loss, Explained</em> series, which explores the biology of hair loss, treatment limitations, and emerging research in hair restoration.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=de2eebe6ccbc" width="1" height="1" alt=""><hr><p><a href="https://medium.com/illumination/nobody-posts-month-four-de2eebe6ccbc">Nobody Posts Month Four</a> was originally published in <a href="https://medium.com/illumination">ILLUMINATION</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[The 539% Hair-Growth Headline Is True. That’s the Problem.]]></title>
            <link>https://medium.com/illumination/the-539-hair-growth-headline-is-true-thats-the-problem-a254d8a797e1?source=rss-4f2829a80b2a------2</link>
            <guid isPermaLink="false">https://medium.com/p/a254d8a797e1</guid>
            <category><![CDATA[pp405]]></category>
            <category><![CDATA[clinical-trials]]></category>
            <category><![CDATA[hair-loss]]></category>
            <category><![CDATA[androgeneticalopecia]]></category>
            <category><![CDATA[clascoterone]]></category>
            <dc:creator><![CDATA[Hair Loss, Explained]]></dc:creator>
            <pubDate>Thu, 27 Aug 2026 10:17:52 GMT</pubDate>
            <atom:updated>2026-08-27T10:17:52.052Z</atom:updated>
            <content:encoded><![CDATA[<h4>Two Phase 3 trials of the same hair loss medication reported 539% and 168% relative improvement. The numbers are real. What patients hear when they read them is something else.</h4><figure><img alt="" src="https://cdn-images-1.medium.com/max/984/1*eFiRSzH_oT7xOBB7yR2aBg.png" /><figcaption>In consultation. Credit: Elithair</figcaption></figure><p>A patient told me in June that the new hair loss medication grows five times more hair than anything we currently have.</p><p>He was not making the number up. Clascoterone 5% solution had just produced the kind of figure that travels quickly online, a 539% relative improvement over placebo in one Phase 3 trial. What went wrong happened on the way from a clinical trial endpoint to a man’s imagination. He heard five times more hair, and that is not what the trial reported.</p><p>I should put my own position on the table before going further. I run a clinic that performs hair transplants, so I have a professional stake in how people understand the alternatives available to them. That makes me more interested rather than less in separating what a study found from what a headline makes it sound like it found.</p><h3>Two trials, two very different headlines</h3><p>Cosmo ran two Phase 3 trials of clascoterone 5% solution in men with androgenetic alopecia, SCALP 1 and SCALP 2. They were identically designed and enrolled 1,465 men between them across the United States and Europe. At six months both met the Target Area Hair Count endpoint with statistical significance.</p><p>One produced a 539% relative improvement versus vehicle. The other produced 168%. Same medication, same design, and a threefold gap in the headline figure.</p><p>That does not mean one trial failed, and it does not mean the compound worked three times better in one group. It does mean we should be careful about claiming to know more than a topline release tells us.</p><p>Cosmo’s chief executive, Giovanni Di Napoli, later told Fierce Pharma that the difference was driven by baseline hair counts rather than by any difference in performance. The full absolute Phase 3 hair count data have still not appeared in a peer reviewed paper, which is why that distinction matters so much. Without those numbers I cannot tell a patient what 539% looked like in hairs per square centimetre, and neither can anyone else reading the press release.</p><h3>A percentage can be accurate and still give you the wrong picture</h3><p>Relative figures need something to be relative to, which sounds obvious right up until the percentage becomes enormous. A treatment can outperform its comparison group by several hundred percent without giving anybody several hundred percent more hair than they had before they started. Those are entirely different statements.</p><figure><img alt="Bar chart: placebo gained one hair per square centimetre, treated gained five. The same four-hair difference expressed as a 400% relative improvement." src="https://cdn-images-1.medium.com/max/1024/1*yr5wolAxOALvsSr2GLb9tg.png" /><figcaption>Illustrative figures, not trial data. Image by the author.</figcaption></figure><p>Cosmo describes the stronger Phase 3 result as a 5.39-fold relative improvement in Target Area Hair Count versus vehicle. It does not say participants finished the trial with 539% more hair on their heads. Strip out the words relative, target area and versus vehicle, though, and you can see how fast the meaning shifts.</p><p>This is the point where I stop looking at the percentage and start looking for the absolute count.</p><h3>The boring number is usually the useful one</h3><p>Hairs per square centimetre will never make as good a headline, and it is still the number I would rather discuss with a patient.</p><figure><img alt="A trichoscopy camera beside a monitor showing magnified scalp with individual hairs inside a green analysis frame." src="https://cdn-images-1.medium.com/max/938/1*76OFPHHeQNYFs86fQBKUhw.png" /><figcaption>TrichoLAB. Credit: Elithair</figcaption></figure><p>We do not have the absolute Phase 3 figures in a peer reviewed publication yet, but an earlier clascoterone proof of concept study gives some sense of scale. At six months the 5% group had a mean increase of 12.7 non-vellus hairs per square centimetre in the target area, against 2.9 for vehicle.</p><p>Those numbers come with a large warning label. It was a small Phase 2 study not powered to show statistically significant differences between groups, and it cannot be used to guess what the unpublished Phase 3 figures will turn out to be. What it does is give the eye a scale. Twelve or thirteen extra hairs in a square centimetre is something I can work with in a consultation, because I can set it against a man’s baseline density and talk about whether a change of that size is likely to be visible to him. The percentage on its own lets me do none of that.</p><p>Even hairs per square centimetre are not the whole cosmetic result, since thickness, distribution and the number of active follicular units all affect what somebody sees in the mirror. Trials measure what their endpoints were designed to measure, while patients tend to be asking something much broader about how their hair will look.</p><h3>PP405 shows another way a promising result grows in transit</h3><p>PP405 is the other experimental treatment I am asked about most at the moment, and the biology behind it is interesting.</p><p>Researchers have known for years that bald scalp in androgenetic alopecia can retain hair follicle stem cells even where certain progenitor populations are greatly reduced. PP405 is built around reactivating dormant follicular stem cells and getting inactive follicular units producing terminal hair again, which is not the same thing as creating new follicles from nothing, though it is a worthwhile target.</p><p>Its Phase 2a trial enrolled 78 men and women who used the topical or vehicle for four weeks and were followed afterwards. Here is the part that tends to disappear online. The study was designed primarily around safety and pharmacokinetics, and it met those objectives, with Pelage reporting that PP405 was well tolerated and that no systemic absorption was detected in blood.</p><p>The hair growth figure everybody repeats came from exploratory efficacy work. At week eight, four weeks after dosing ended, 31% of treated men with a higher degree of hair loss showed more than a 20% increase in hair density, against nobody in the corresponding placebo group.</p><p>That is interesting, and it is also an efficacy signal from a subgroup inside a 78-person early stage study that was not powered primarily to demonstrate efficacy. Both things are true at the same time.</p><p>Further Phase 2a findings were discussed at the American Academy of Dermatology meeting in March 2026, including observations on terminal hairs and active follicular units, and Pelage is preparing for late stage development. What we do not have is the kind of large replicated Phase 3 dataset that would let anyone talk about PP405 as though its clinical effect were settled.</p><h3>The part of the clascoterone data I find more useful than 539%</h3><p>Cosmo released a twelve month Phase 3 follow-up in April 2026. Among responders from the initial six month phase who entered the extension, some continued on clascoterone and others were switched to vehicle. The men who stayed on treatment kept improving, while those switched away experienced a reduction in their treatment gains. Cosmo reported a 2.39-fold difference in Target Area Hair Count between the two.</p><p>This got nowhere near the attention 539% did, and for a man deciding whether to begin a treatment he will be using for decades, it is arguably the more useful half of the story, because it says something about how dependent the result is on continuing.</p><p>It also carries a lesson about reading trials generally, which is to check who actually entered the extension. Here the twelve month phase involved people who had already responded during the first six months. It was not a twelve month follow-up of all 1,465 original participants, and that is the kind of detail that rarely survives the trip to social media.</p><h3>And no, we cannot compare it with finasteride yet</h3><p>I have already seen the clascoterone percentage set beside finasteride results with a winner declared. There has been no head to head trial establishing anything of the sort.</p><p>Taking an effect estimate from one study and placing it next to a number from another does not turn the pair into a randomised comparison, not when the populations, protocols, endpoints and baselines are all different. Until somebody compares the two directly, the honest answer is that we do not know which performs better.</p><h3>Where things stand</h3><p>As of August 2026, clascoterone 5% solution has completed its Phase 3 programme and twelve month follow-up. It is not approved for androgenetic alopecia anywhere. Cosmo says it is preparing a United States filing for the first quarter of 2027 and a European one for the second. The full Phase 3 efficacy dataset has not appeared in a peer reviewed publication, so the 539% and 168% figures should still be described as what they are, which is sponsor-reported topline results.</p><p>PP405 sits further back. Its Phase 2a study is complete, additional findings were presented at AAD 2026, and Pelage has said it is preparing late stage studies. It remains investigational.</p><p>That may sound less exciting than the posts circulating online. I find it considerably more interesting.</p><figure><img alt="Dr. Balwi viewing a scalp planning diagram on screen. The diagram shows a head from above divided into numbered zones, with the donor area outlined in blue and a graft number added by hand." src="https://cdn-images-1.medium.com/max/953/1*i6Gmfq05UjXXUx6o_As0mw.png" /><figcaption>Where a number stops being a percentage and becomes a plan for one specific head. Credit: Elithair</figcaption></figure><h3>What I look at instead</h3><p>The next time somebody shows me a treatment with a very large percentage attached, the percentage is the last thing I look at. I want the absolute number, what happened in the comparison group, whether the result was the trial’s primary endpoint or an exploratory subgroup, and what things looked like six months later.</p><p>Answering those questions usually makes the headline smaller. It also turns it into something I can discuss properly with the man sitting in front of me, which a percentage on its own has never once given me.</p><h4>Selected References</h4><p><a href="https://www.cosmohealthconfidence.com/news/11029858-breezula-phase-iii-results">Cosmo Pharmaceuticals. Phase III Topline Results from SCALP 1 (NCT05910450) and SCALP 2 (NCT05914805) for Clascoterone 5% Solution. 3 December 2025.</a><br><a href="https://www.cosmohealthconfidence.com/news/98958067-clascoterone-12-month-safety-results-ende">Cosmo Pharmaceuticals. Phase III 12-Month Data for Clascoterone 5% Topical Solution. 15 April 2026.</a><br><a href="https://www.fiercepharma.com/pharma/cosmo-shares-zoom-results-2-male-pattern-hair-loss-trials">Dunleavy K. Cosmo shares zoom with results of two male-pattern hair-loss trials. Fierce Pharma. 3 December 2025.</a><br><a href="https://pelagepharma.com/press-releases/pelage-pharmaceuticals-announces-positive-phase-2a-clinical-trial-results-for-pp405-in-regenerative-hair-loss-therapy/">Pelage Pharmaceuticals. Positive Phase 2a Clinical Trial Results for PP405 (NCT06393452). 17 June 2025.<br></a><a href="https://pelagepharma.com/press-releases/pelage-pp405-aad-2026/">Pelage Pharmaceuticals. PP405 and Follicular Regeneration at the AAD Annual Meeting 2026. 18 March 2026.</a></p><h4>About the Author</h4><p><strong>Dr. Aziz Balwi<br></strong>Medical Director<br><em>Hair Loss, Explained</em></p><p>Dr. Aziz Balwi specializes in hair restoration with a clinical focus on donor management, long-term transplant planning, and patient-specific treatment strategies.</p><p><strong>Hair Loss, Explained<br></strong>This article is part of the <em>Hair Loss, Explained</em> series, which explores the biology of hair loss, treatment limitations, and emerging research in hair restoration.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=a254d8a797e1" width="1" height="1" alt=""><hr><p><a href="https://medium.com/illumination/the-539-hair-growth-headline-is-true-thats-the-problem-a254d8a797e1">The 539% Hair-Growth Headline Is True. That’s the Problem.</a> was originally published in <a href="https://medium.com/illumination">ILLUMINATION</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
    </channel>
</rss>